focus -WSS

focus

author：knowledge 2025-10-02 19:19:21 - browse：6

Photograph of Bill Cassidy. -- health policy coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — With Novo Nordisk’s Wegovy and Ozempic hitting blockbuster sales and a new rival approved this week, everyone in Washington is thinking about how to manage the crashing wave of weight loss drug costs.

The explosive national demand for weight management therapies and diabetes drugs like Ozempic — all of which are indicated for indefinite use — has become central in an ongoing policy debate over high drug costs and controversial tactics to manage them, including President Biden’s plan to let the government negotiate directly with pharmaceutical companies. Seventy percent of Americans could qualify for these medicines.

Sen. Bill Cassidy (R-La.), the highest-ranking Republican on the Senate’s health policy committee, has vehemently opposed the negotiation plan, arguing it reduces incentives to develop new therapies and may not actually reduce patients’ costs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Biotech lab space demand falls sharply

Wikipedia

focus

WSS

Biotech stock slump in 2023: awaiting the turnaround

How Vertex's cystic fibrosis drug is changing patients' lives

CommonSpirit Health keeps growing, even as it loses money

CDC's new outbreak response network to include Northeastern

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Lasker Awards 2023: Winners in biomedical research

Wikipedia

focus

focus

Sports medicine is finally prioritizing gender equality

CDC advisers recommend seasonal use of Pfizer RSV shot

Novavax promises a turnaround & Lilly roils the obesity market

Medical student insurance fails on mental health care coverage

Sports medicine is finally prioritizing gender equality

Microbiome research is starting to find links to chronic diseases

Medical records are filled with copy

How AI helped researchers track recovery from depression

Medicare details structure of new drug price negotiation program

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

entertainment

CommonSpirit Health keeps growing, even as it loses money

It's been 20 years since Dolly the sheep. Where's my clone?

EpiPen alternative approval delay highlights citizen petition issue

Emergency workers more likely to restrain Black patients: study

STAT Virtual Event: Putting AI to the Test

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Wikipedia

focus

hotspot

explore